secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001599298-22-000109
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics appoints Dr. Robert Booth to Board of Directors; Dr. Urte Gayko resigns from Board
--------------------------------------------------------------------------------

- Dr. Robert Booth appointed to Board effective September 28, 2022; will join Nominating and Corporate Governance Committee.
- Dr. Booth initiated the BTK inhibitor program at Celera Genomics that led to Pharmacyclics' blockbuster drug Imbruvica (ibrutinib).
- Dr. Booth received stock option grant per non-employee director compensation policy and standard indemnification agreement.
- Dr. Urte Gayko resigned from Board to focus on her full-time role as Head of Regulatory, Safety, and Quality; resignation not due to any disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/smmt-20220928.htm
  HTML page:      https://secwatch.observer/filing/0001599298-22-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer